spacer
home > ict > winter 2017 > up and coming
PUBLICATIONS
International Clinical Trials

Up and Coming

In Sub-Saharan Africa, South Africa remains the optimal location for trials. It accounts for approximately 58% of the total clinical studies conducted within the region and continues to operate as a regional hub. South Africa’s regulatory framework and relatively high level of healthcare infrastructure and public health system make it attractive for trials (1).

The majority of trials that take place in Sub-Saharan Africa are grant-funded and focus on infectious diseases such as HIV, tuberculosis (TB) and malaria. Countries like Burkina Faso, Ghana, Kenya, Malawi, Mali and Tanzania are emerging as viable locations. Both pharmaceutical companies and CROs have been expanding their presence throughout Kenya in the east and Ghana in the west, whereas Nigeria is emerging as a satellite hub to support the growth of clinical trials in this region. Efforts should be taken to harmonise regulatory protocols for the conduct of studies across the continent as most of the guidelines currently vary from country to country.

Development Opportunities

To promote the conduct of clinical research in the region, the Pan African Clinical Trials Registry (PACTR) was established by the South African Cochrane Centre in collaboration with the European and Developing Countries Clinical Trials Partnership and the Cochrane Infectious Disease Group. It is an official registry affiliated with the WHO Network of Primary Registers. The PACTR also provides data to the central WHO International Clinical Trials Registry Platform, so that studies listed in the archive are available through a global platform (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Saravanan Thangaraj is a Senior Research Analyst in the Transformational Health group at Frost & Sullivan. He has over three years of experience in management consulting, has advised clients on strategy and business and has also authored many off-the-shelf industry insight reports during his time at the company. Saravanan’s experience includes biotechnology, pharma, life sciences, in vitro diagnostic devices and health systems. He holds a Bachelor of Technology in Biotechnology and a Master of Business Administration from PSG College of Technology, India.
spacer
Saravanan Thangaraj
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta and Mologic Enter Research and Product Development Collaboration Agreement

Avacta announces the formation of a collaborative research partnership
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

6th Annual Cancer Vaccines Conference

27-28 September 2017, Copthorne Tara Hotel, London UK

Cancer Vaccines 2017: Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies. SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement